About Company

Chengdu StarRay Therapeutics Co., Ltd.

Innovative Biotechnology Company in Clinical Stage

                                
Chengdu StarRay Therapeutics Co., Ltd. was established on August 22, 2025, in Chengdu Tianfu International Bio-Town.. As Fosun Pharma’s innovation platform dedicated to radiopharmaceuticals, StarRay was founded and is led by a team of accomplished scientists with extensive international experience and a global perspective.
With radioligand therapy (RLT) at the core of its strategy, the company focuses primarily on the research, development, and clinical translation of theranostic radiopharmaceuticals for oncology. StarRay is building comprehensive capabilities across core radiopharmaceutical technologies, product development, and commercial-scale manufacturing, with the goal of establishing an innovation-driven, globally competitive radiopharmaceutical technology platform and developing high-value diagnostic and therapeutic products.
Leveraging Fosun Pharma’s global resources and industrial synergies, StarRay is building integrated capabilities across the entire radiopharmaceutical value chain—from research and development to manufacturing, supply, and clinical application. The company places particular emphasis on drug design and development, industry collaboration, clinical translation, and commercialization. Through these efforts, StarRay aims to advance nuclear medicine beyond conventional diagnostics and radiotherapy toward greater precision and integrated theranostics.
Driven by the dual engines of in-house innovation and ecosystem partnerships, StarRay is developing a diversified, multi-tiered product pipeline while continuously strengthening its technological capabilities and improving the efficiency of product development and commercialization. The company is committed to delivering safe, precise, and accessible diagnostic and therapeutic solutions to patients worldwide.